Hospital Universitario Virgen del Rocío -ko ikertzaileekin lankidetzan egindako argitalpenak (38)

2024

  1. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

    Viruses, Vol. 16, Núm. 2

2023

  1. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 7

2021

  1. Case-control analysis of the impact of anemia on quality of life in patients with cancer: A Qca study analysis

    Cancers, Vol. 13, Núm. 11

  2. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

    Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810

  3. Progression to hepatitis C virus micro-elimination in people living with HIV in Spain

    Clinical Microbiology and Infection

2020

  1. A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: Quality of life in cancer (QCA) study

    Cancers, Vol. 12, Núm. 1

  2. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: The BACS score

    European Respiratory Journal, Vol. 56, Núm. 6

  3. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 8, Núm. 3, pp. 353-359.e1

2019

  1. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

  2. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients

    Medicine (United States), Vol. 98, Núm. 32

  3. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  4. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

    HIV Medicine, Vol. 20, Núm. 6, pp. 359-367

  5. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

    PLoS ONE, Vol. 14, Núm. 8

  6. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 634-641

2018

  1. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis

    PLoS ONE, Vol. 13, Núm. 7

2017

  1. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

    Chest, Vol. 151, Núm. 3, pp. 564-571

  2. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494

2016

  1. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens

    PLoS ONE, Vol. 11, Núm. 2

  2. Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study

    PLoS ONE, Vol. 11, Núm. 5

  3. No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: A multicentric retrospective study from 2000-2014

    BMC Infectious Diseases, Vol. 16, Núm. 1